Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant PLD, Albumin-Bound Paclitaxel, and Trastuzumab in HER2+ Breast Cancer
NCT03994107Phase 2Unknown
- Sponsor
- Peking Union Medical College
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin in HER2-positive breast cancer, sponsored by Peking Union Medical College. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03994107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03994107.